Condition: Thyroid Cancer · Thyroid · Refractory Thyroid Cancer · Sponsor: Memorial Sloan Kettering Cancer Center
The purpose of this study to learn more about the use of redifferentiating medications as a standard treatment for radioactive iodine/RAI-refractory thyroid cancer. This study is a registry study.
This description comes directly from the study's public registry record.
Laura Boucai, MD · 646-608-3906 · boucail@mskcc.org
Alan Ho, MD, PhD · 646-608-3774 · hoa@mskcc.org
Always discuss trial participation with your own doctor first.
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05733013